XenoTech, LLC offers drug inhibition, enzyme induction, and drug metabolism studies for pharmaceutical, chemical, food, academic, and regulatory organizations in the United States, Japan, Europe, and internationally. It provides various in vitro tools, including hepatocytes, microsomes, S9, recombinant cytochrome P450, substrates and metabolites, and antibodies. The company's services include enzyme inhibition, which predicts the potential for compounds to inhibit the metabolism of other drugs and risk adverse reactions; reaction phenotyping (enzyme mapping), which is used to determine the metabolic pathways involved in biotransformation of compounds; and species comparisons, which identify the non-human species. XenoTech, LLC also offers consultation services to clients and regulatory agencies; and research services. In addition, it distributes Bactosomes and SOLVO transporter products in the United States and Canada. The company offers its products through distributors in Belgium, France, Germany, Iberia, Ireland, Italy, Japan, Singapore, Sweden, Denmark, Finland, Norway, the Netherlands, and the United Kingdom. XenoTech was founded in 1994 and is based in Lenexa, Kansas.